Ypsomed Aktie
| 422,00CHF | -1,50CHF | -0,35% |
WKN: A0B8VP / ISIN: CH0019396990
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 824 | 1 831 | 1 978 | 2 296 | 2 644 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,22 | 0,25 | 0,25 | 0,24 | 0,28 |
Bilanz (in Mio. CHF) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 185 | 194 | 208 | 338 | 427 |
| Summe Anlagevermögen | 533 | 563 | 654 | 763 | 903 |
| Summe Aktiva | 718 | 757 | 862 | 1 101 | 1 330 |
Bilanz (in Mio. CHF) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 322 | 364 | 300 | 484 | 651 |
| Summe Eigenkapital | 395 | 393 | 562 | 618 | 680 |
| Summe Passiva | 718 | 757 | 862 | 1 101 | 1 330 |
Adresse
| Brunnmattstrasse 6, 3401 Burgdorf | |
| Telefon | +41 (34) 424-41-11 |
| Internet | http://www.ypsomed.com |
Management
|
Frank Mengis
Chief Operating Officer |
|
Gilbert Achermann
Chairman |
|
Marie-Pierre Zerr
Director |
|
Martin C. Münchbach
Independent Non-Executive Director |
|
Michael Zaugg
Chief Corporate Officer |
|
Nicolas Meyer
Chief Legal Officer |
|
Paul R. Fonteyne
Independent Non-Executive Director |
|
Samuel Künzli
Chief Financial Officer & Member-Executive Board |
|
Sebastien Delarive
Co-Chief Business Officer |
|
Simon Michel
Chief Executive Officer & Director |
|
Thomas Kutt
Head-Investor Relations |
|
Ulrike Bauer
Co-Chief Business Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.